California-based Graph AI, a company focused on patient safety, has secured $3 million in a Seed funding round led by Bessemer Venture Partners. This investment will help the company advance its product development, grow its engineering team, and support its expansion into new markets.

Graph AI is positioning itself as a modern alternative in the $8 billion pharmacovigilance market. The company’s platform uses artificial intelligence to help pharmaceutical companies manage drug safety monitoring more effectively.

Tackling an $8 Billion Challenge

Pharmacovigilance is the practice of monitoring the effects of medical drugs after they have been licensed for use, a requirement for all pharmaceutical companies. This involves continuously detecting and reporting adverse drug events throughout a drug’s entire lifecycle. Traditionally, this work has been outsourced to large service firms where teams manually collect and report data, a process that is both time-intensive and susceptible to errors.

The founders said: “The life sciences industry continues to grapple with outdated technology, fragmented point solutions, data silos, and manual handoffs that hinder decision-making and elevate compliance risks. At Graph, we’re addressing these challenges with a unified, AI-native safety platform that integrates context, compliance, and intelligence into a single seamless ecosystem. Our vision is to make patient safety smarter, faster, and more connected, empowering pharmaceutical enterprises to achieve safer outcomes, stronger regulatory confidence, and exponential efficiency across safety operations.”

From Manual Labor to Intelligent Automation

With the new capital, Graph AI plans to refine its platform and add new features. The company will also focus on hiring more engineers to support this development. The goal is to move the industry from manual workflows to a more automated system that keeps humans involved only for specific, mandated steps.

By integrating AI, Graph allows companies to improve the accuracy of medical reviews while maintaining regulatory compliance. According to the company, early customers have already reported up to 70% greater efficiency and 90% faster regulatory submissions, along with significant cost savings. The platform is built to provide full traceability, ensuring that all processes are ready for audits.

The Team Behind the Technology

Graph AI was founded in 2024 by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO). The founding team brings experience from major technology and service companies, including Google, ServiceNow, and Infosys.

The company distinguishes itself by offering a single, AI-powered platform designed specifically for patient safety. This approach is intended to avoid the fragmented tools and data silos common in the life sciences industry. In just over a year, Graph AI has built a strong customer base and a pipeline that covers more than 7,000 drugs.

A Strategic Partnership

The investment from Bessemer Venture Partners signals confidence in Graph AI’s approach to solving a long-standing industry problem. The firm sees potential in how AI can transform traditional, labor-based business models into ones driven by intelligence.

Nithin Kaimal, Partner at Bessemer Venture Partners, said: “We’re excited to partner with Graph AI as they redefine labour intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize accuracy and scalability. At Bessemer, we’re deeply optimistic about the transformative potential of AI to reimagine traditional services models as for the first time, delivery is shifting from labour arbitrage to intelligence arbitrage, empowering enterprises to work with firms that deliver faster, smarter, and more adaptive solutions. We look forward to supporting the Graph team as they continue to scale new heights.”

Origianl Creator: Ekaterina Pisareva
Original Link: https://justainews.com/companies/funding-news/pharmacovigilance-ai-startup-graph-raises-3m-seed/
Originally Posted: Thu, 16 Oct 2025 15:58:20 +0000